Pharvaris (NASDAQ:PHVS) Shares Gap Up – Still a Buy?

Pharvaris (NASDAQ:PHVS)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $15.01, but opened at $15.40. Pharvaris shares last traded at $15.10, with a volume of 6,043 shares.

Analyst Ratings Changes

Separately, JMP Securities boosted their target price on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Stock Up 7.7 %

The firm has a 50 day moving average of $17.26 and a 200 day moving average of $19.17. The firm has a market cap of $839.25 million, a price-to-earnings ratio of -5.73 and a beta of -3.02.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PHVS. Legal & General Group Plc increased its position in Pharvaris by 11.2% in the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock worth $189,000 after buying an additional 994 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock valued at $735,000 after acquiring an additional 1,356 shares during the period. Deutsche Bank AG boosted its holdings in Pharvaris by 13.0% during the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company’s stock valued at $348,000 after acquiring an additional 2,087 shares during the period. JPMorgan Chase & Co. raised its position in Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after purchasing an additional 2,847 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Pharvaris during the 3rd quarter valued at approximately $57,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.